HEPA Insider Trading Activity and SEC Form 4 Filings
HEPA insider trading summary
Over the past 12 months, insiders at Hepion Pharmaceuticals, Inc. (HEPA) reported 7 open-market purchases worth $835K by 6 insiders and no sales on SEC Form 4. Net insider buying was $835K.
Latest HEPA insider buys and sells
| Date | Insider | Role | Type | Value |
|---|---|---|---|---|
| Sep 29, 2026 | Danina Fisher | Director | Buy | $10K (200,000 @ $0.05) |
| Aug 3, 2026 | Sireesh Appajosyula | Chief Operating Officer | Buy | $100K (2,000,000 @ $0.05) |
| Aug 3, 2026 | Gary S. Stetz II | Director | Buy | $25K (500,000 @ $0.05) |
| Aug 3, 2026 | Vincent S LoPriore | Executive Chairman | Buy | $100K (2,000,000 @ $0.05) |
| Aug 3, 2026 | Gary S. Stetz | Interim CEO | Buy | $100K (2,000,000 @ $0.05) |
| Aug 3, 2026 | Vincent S LoPriore | Executive Chairman | Buy | $400K (8,000,000 @ $0.05) |
| Aug 3, 2026 | Michael J. Purcell | Director | Buy | $100K (2,000,000 @ $0.05) |
| Nov 27, 2023 | Peter Wijngaard | Director | Buy | $8K (2,500 @ $3.05) |
| Nov 24, 2023 | Peter Wijngaard | Director | Buy | $8K (2,500 @ $3.09) |
| Sep 19, 2023 | Peter Wijngaard | Director | Buy | $6K (1,000 @ $5.64) |
Source: SEC Form 4 filings. Open-market purchases (code P) and sales (code S) only; option exercises, grants and gifts are excluded.